EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor

Term ID

CHEBI:88286

Synonyms

ATP:protein phosphotransferase (MAPKKK-activated) inhibitor
ATP:protein phosphotransferase (MAPKKK-activated) inhibitors
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitors
EC 2.7.12.2 inhibitor
EC 2.7.12.2 inhibitors
MAP kinase kinase 4 inhibitor
MAP kinase kinase 4 inhibitors
MAP kinase kinase 7 inhibitor
MAP kinase kinase 7 inhibitors
MAP kinase kinase inhibitor
MAP kinase kinase inhibitors
MAP kinase or ERK kinase inhibitor
MAP kinase or ERK kinase inhibitors
MAP2K inhibitor
MAP2K inhibitors
MAPKK inhibitor
MAPKK inhibitors
MAPKK1 inhibitor
MAPKK1 inhibitors
MEK inhibitor
MEK inhibitors
MEK1 inhibitor
MEK1 inhibitors
MEK2 inhibitor
MEK2 inhibitors
mitogen-activated protein kinase kinase (EC 2.7.12.2) inhibitor
mitogen-activated protein kinase kinase (EC 2.7.12.2) inhibitors
mitogen-activated protein kinase kinase inhibitor
mitogen-activated protein kinase kinase inhibitors
MKK inhibitor
MKK inhibitors
MKK2 inhibitor
MKK2 inhibitors
MKK4 inhibitor
MKK4 inhibitors
MKK6 inhibitor
MKK6 inhibitors
MKK7 inhibitor
MKK7 inhibitors
STK27 inhibitor
STK27 inhibitors

(all 41)

Definition

An EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor that inhibits the action of mitogen-activated protein kinase kinase (EC 2.7.12.2).

References

Wikipedia:Mitogen-activated_protein_kinase_kinase

Ontology

ChEBI ( EBI )

Relationships

is a type of: EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor

EC 2.7.12.* [dual-specificity kinases (those acting on Ser/Thr and Tyr residues)] inhibitor Show first 5 Terms
inverse has_role: GDC-0623 PD 0325901 pimasertib SL-327

GDC-0623 PD 0325901 pimasertib SL-327 Show first 5 Terms

Phenotype

Phenotype resulting from EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor

Fish	Conditions	Phenotype	Term	Figures
TL	chemical treatment: EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	fin regeneration decreased efficacy, abnormal	EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	Fig. 6 from Hale et al., 2017
WT	chemical treatment: EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	thymus rag1 expression decreased amount, abnormal	EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	Fig. 3 from Sertori et al., 2016

1 - 2 of 2

Show

Phenotype where environments contain EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor

Phenotype modified by environments containing EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor

Fish	Modification	Conditions	Phenotype	Term	Figures
EKW + MO5-kmt2d	ameliorated	chemical treatment by environment: EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	Meckel's cartilage distance ceratohyal cartilage, ameliorated mandibular arch skeleton morphology, ameliorated convergent extension involved in gastrulation process quality, ameliorated	EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	Fig. 2 from Tsai et al., 2018
umc1Tg (AB)	ameliorated	chemical treatment by environment: EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	whole organism Melanin amount, ameliorated melanocyte amount, ameliorated	EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	Fig. 7 from Herrero et al., 2015

1 - 2 of 2

Show

Human Disease Model